Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 25 (2), 139-148

Metabolomics in Chronic Lung Diseases

Affiliations
Review

Metabolomics in Chronic Lung Diseases

Shabarinath Nambiar et al. Respirology.

Abstract

Chronic lung diseases represent a significant global burden. Their increasing incidence and complexity render a comprehensive, multidisciplinary and personalized approach to each patient, critically important. Most recently, unique biochemical pathways and disease markers have been identified through large-scale metabolomic studies. Metabolomics is the study of metabolic pathways and the measurement of unique biomolecules in a living system. Analysing samples from different compartments such as bronchoalveolar lavage fluid (BALF) and plasma has proven useful for the characterization of a number of pathological conditions and offers promise as a clinical tool. For example, several studies using mass spectrometry (MS) have shown alterations in the sphingolipid metabolism of chronic obstructive pulmonary disease (COPD) sufferers. In this article, we present a practical review of the application of metabolomics to the study of chronic lung diseases (CLD): COPD, idiopathic pulmonary fibrosis (IPF) and asthma. The insights, which the analytical strategies employed in metabolomics, have provided to the dissection of the biochemistry of CLD and future clinical biomarkers are explored.

Keywords: asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; lung; metabolomics.

Similar articles

See all similar articles

Cited by 2 PubMed Central articles

References

REFERENCES

    1. Papaioannou O, Karampitsakos T, Barbayianni I, Chrysikos S, Xylourgidis N, Tzilas V, Bouros D, Aidinis V, Tzouvelekis A. Metabolic disorders in chronic lung diseases. Front. Med. 2017; 4: 246.
    1. Zhao H, Dennery PA, Yao H. Metabolic reprogramming in the pathogenesis of chronic lung diseases, including BPD, COPD, and pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2018; 314: L544-54.
    1. Kao CC, Hsu JW-C, Bandi V, Hanania NA, Kheradmand F, Jahoor F. Glucose and pyruvate metabolism in severe chronic obstructive pulmonary disease. J. Appl. Physiol. 2012; 112: 42-7.
    1. Karampitsakos T, Gourgoulianis KI. Asthma-COPD overlap syndrome (ACOS): single disease entity or not? Could exhaled nitric oxide be a useful biomarker for the differentiation of ACOS, asthma and COPD? Med. Hypotheses 2016; 91: 20-3.
    1. Kang YP, Lee SB, Lee J-m, Kim HM, Hong JY, Lee WJ, Choi CW, Shin HK, Kim D-J, Koh ES et al. Metabolic profiling regarding pathogenesis of idiopathic pulmonary fibrosis. J. Proteome Res. 2016; 15: 1717-24.

LinkOut - more resources

Feedback